N/A
N=49
Pharmacy-based Pre-exposure Prophylaxis
Human Immunodeficiency Virus
Bottom Line
View on ClinicalTrials.gov: NCT04393935 ↗Enrolled (actual)
49
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Number of Participants Continuing PrEP — 2 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Pharmacy Delivered PrEP Intervention (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Emory University
- Primary completion
- May 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Continuing PrEP |
2 | — |
Summary
The proposed research will develop a culturally appropriate pharmacy pre-exposure prophylaxis (PrEP) delivery model for black men who have sex with men (BMSM) who live in high poverty, racial minority neighborhoods. Increasing access to PrEP through pharmacies has the potential to increase PrEP uptake among BMSM thereby reducing HIV incidence and racial inequities in HIV.
Eligibility Criteria
Inclusion Criteria
- Consent to participate in the online screener
- Can speak and read English without any help
- Test negative for HIV
- Agree to receive medication from the pharmacy
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT04393935). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.